The Role of Pharma Companies in Rising Medical Costs
by Kashvi Mahesh
What if the very companies that create lifesaving drugs are also the reason so many people can’t afford them?
Around the globe, the price of medication continues to outpace wages and inflation. The result: patients rationing prescriptions, governments straining budgets, and growing distrust of an industry built on innovation and profit. Among the web of insurers, regulators, and pharmacies, pharmaceutical companies (“Big Pharma”) sit at the centre. Their decisions ripple across the entire healthcare system, shaping both access and affordability.
Key Drivers Behind High Drug Prices: What Pharma Companies Do
Here are some of the main ways in which pharmaceutical firms contribute to rising medication costs:
1. High Research & Development (R&D) Costs, and Risk of Failure
Developing a new drug is expensive and long-term. Clinical trials, regulatory approval, safety monitoring, failures, etc., all add up.
Studies show that R&D costs per new medicine can range from ~US$944 million to US$2.8+ billion (adjusted to recent US inflation levels) when failures are included.
Pharma companies often argue that prices must reflect not just the successes, but also the many failed attempts.
2. Patent Protection, Market Exclusivity, and “Evergreening”
Patents give exclusive rights to sell a drug for a period of time (often 10-12 years in many markets), which lets companies set higher prices because there’s no generic competition.
Strategies like evergreening (minor modifications to existing drugs, new delivery methods, or reformulations) can extend exclusivity or delay generic competition. This keeps prices high longer.
3. Pricing Power & Market Demand
For many newer and breakthrough drugs—especially those that treat serious or life-threatening conditions, or offer a unique benefit—pharma can price based on what the market (insurers, public health systems, patients) will bear rather than based strictly on cost.
When there is little or no competition, price increases can happen with less resistance. Some companies raise the price of already-marketed drugs, even in the absence of new improvements, because they can.
4. Marketing, Sales, and Administrative Costs
Pharmaceutical companies spend heavily not just on science, but also on marketing, advertising (including direct-to-consumer in some countries), sales forces, regulatory compliance, quality control, global supply chains, etc. These add to overall expenses that must be recovered.
Sometimes the “non-scientific” costs (sales, general and administrative, advertising) exceed or rival R&D spending in large companies.
5. Regulatory Environment & Price Negotiations
In many countries, regulation of drug prices is weak or absent; pharma companies often have leeway to set cost-plus prices, markups, or list prices with rebates, etc.
Where there is regulation, companies sometimes find workarounds (patent tweaks, reformulations, changing the molecule slightly, etc.) to avoid strict price caps.
6. Profit Motives & Shareholder Expectations
Pharma is often a high-profit-margin business. Investors expect returns. The profits on blockbuster drugs (those with very large markets, sometimes life-saving) can be huge. Companies use part of these profits to reinvest, but also to maintain operations, pay dividends, etc.
Critics argue that profit motives lead to pricing that prioritises revenue over affordability. There is debate about what level of profit is “fair” vs. what is socially acceptable.
What Evidence Suggests Pharma Pricing Doesn’t Always Match Cost or Value
It’s important to note that some of the narratives pharma companies promote—that prices must rise because of R&D costs, or that more innovation always requires higher prices—are contested. Key evidence:
A 2022 study in JAMA Network Open found no clear relationship between the amount spent on R&D for a new drug and its price. Also, there was no consistent link between the therapeutic value of the drug and its price.
Another analysis (BMJ) showed that in the period 1999-2018, major biopharma companies spent more on selling, general, and administrative (SG&A) costs than on R&D, implying that non-development costs are a major part of expenditures.
Impacts: Why Rising Drug Prices Matter Financially
From a financial literacy perspective, rising drug prices affect both macro and micro scales:
Out-of-Pocket Costs: For individuals, especially in systems without full insurance or where co-pays/deductibles are high, medicine costs can consume large portions of income. Chronic disease management becomes expensive.
Insurance Premiums & Government Budgets: Rising drug costs feed into higher insurance premiums, more strain on public health systems, and higher government expenditure on subsidies or public insurance.
Access and Inequality: When prices rise more than people’s ability to pay, access suffers. Poorer populations, or those without insurance, are disproportionately hit.
Financial Trade-offs: People may skip doses, purchase counterfeit or cheaper alternatives, or delay treatment—leading to worse health outcomes and potentially higher downstream medical costs.
Potential Solutions and What Stakeholders Can Do
If we understand pharma companies’ roles, then we can also think about ways to curb excessive drug cost growth while preserving incentive for useful innovation. Some options include:
1. Stronger Price Regulation
Government negotiation of drug prices (for public insurance).
Caps or controls on price increases (tying them to inflation or other benchmarks).
Transparent pricing mandates.
2. Patent Reform
Limit evergreening, stricter standards for new patents/reformulations.
Shorter exclusivity periods in certain cases.
Facilitating earlier entry of generics or biosimilars.
3. Encouraging Competition
Support for generic manufacturers.
Faster regulatory approvals for generics/biosimilars.
Reducing barriers to entry.
4. Transparency in Cost Components
Requiring companies to disclose cost breakdowns (R&D, marketing, profit margin).
Publishing therapeutic value: showing what benefit a drug provides relative to its cost.
5. Alternative Incentive Models
“Prize funds” or rewards for innovation that are not tied purely to monopoly pricing.
Public funding of early-stage R&D so that later pricing pressures are reduced.
Risk sharing or subscription models (where the payer pays a fixed fee for access, etc.).
6. Patient & Purchaser Empowerment
Insurance design that promotes the use of lower‐cost alternatives.
Comparative effectiveness and cost‐benefit research to guide choices.
Policy tools like out-of-pocket caps for patients.
Case Studies & Examples
Weight-loss drugs (USA): Recently, drugs like Mounjaro and Ozempic have very high monthly prices. Between long development times, risk, and the potential market size, pharma companies justify high costs — but affordability is a major concern.
India: Some practices (e.g. companies tweaking reference molecules to escape price control orders) have been reported. Pharma firms sometimes request exemptions from price control for low-cost formulations, citing the cost of compliance or rational margin trade-offs.
Balancing Innovation with Affordability
Innovation is valuable. New drugs can save lives, reduce suffering, and even reduce other costs (hospitalisations, surgeries, etc.).
But innovation should not automatically imply prohibitive cost for patients. The balance between rewarding innovation and keeping medicines affordable is critical.
The Takeaway
The pharmaceutical industry stands at the centre of the rising cost of medications, but it does not stand alone. Every stage, from research and patent protection to marketing and competition, influences the final price patients pay.
For both citizens and policymakers, understanding these mechanisms is a cornerstone of financial and health literacy. Transparency, accountability, and smart regulation are key to aligning innovation with affordability so that progress in medicine doesn’t come at the expense of access.
At an individual level, awareness also empowers action: comparing prices, choosing generics, exploring patient assistance programs, and optimising insurance coverage can all make essential treatments more attainable.
References:
